This review considers antiangiogenic therapy for colorectal, gastric, hepatocellular and pancreatic cancer. The mechanism of action and application of bevacizumab are emphasized, but other potential antiangiogenic targets and therapies are also discussed. Nature Clinical Practice Gastroenterology & Hepatology
Kris V. Kowdley, MD, FACP, provides insight into the latest trends in the treatment of hepatitis B, as framed by data presented at AASLD 2007. Medscape Gastroenterology
Eradication rates of Helicobacter pylori in children are higher with sequential therapy compared with standard triple therapy, a Polish team reports in the Journal of Pediatrics online March 4. Reuters Health Information
Zobair M. Younossi, MD, MPH, FACP, FACG, discusses the most recent findings regarding new approaches to the treatment of HCV infection, with special focus on the STAT-C regimens. Medscape Gastroenterology
Bret Lashner, MD, explores current and emerging issues in nonbiologic strategies for inflammatory bowel disease, based on key data presented at ACG 2008. Medscape Gastroenterology
